Including A Step Of Forming, Releasing, Or Exposing The Antigen Or Forming The Hapten-immunogenic Carrier Complex Or The Antigen, Per Se Patents (Class 435/961)
-
Patent number: 11460475Abstract: A composition of a bilimbin stock and a method of preparation are provided. In one aspect of the invention, the composition includes a base solution. The composition further includes a carbonate salt. Additionally, the composition includes bilimbin. Furthermore, the composition includes human serum albumin.Type: GrantFiled: July 31, 2019Date of Patent: October 4, 2022Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Sudipa Galgalkar, Ishita Chakraborty, Ragavendar Ms, David Ledden
-
Patent number: 8975384Abstract: The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): X1-Tyr-X2-Gly-Gln-X3??(I) (wherein X1, X2 and X3 are the same or different and each represent any amino acid residue) and an antibody against the tag peptide. By combined use of the tag peptide and antibody of the present invention, a system that enables proteins expressed from cloned genes to be highly purified in an inexpensive and easy manner can be established.Type: GrantFiled: December 18, 2008Date of Patent: March 10, 2015Assignee: Osaka UniversityInventor: Junichi Takagi
-
Patent number: 8399633Abstract: During the production of recombinant proteins from gram negative bacteria, lipopolysaccharides (LPS, endotoxin) are released along with the protein of interest. In many instances, LPS will copurify with the target protein due to specific or non-specific protein-ILPS interactions. We have investigated the ability of alkanediols to effect the separation of LPS from protein-LPS complexes while the complexes are immobilized on anion or cation exchange chromatographic media. Alkanediols provide a safer alternative to the use of other organics such as alcohols or acetonitrile due to their lower toxicity and decreased flammability. In addition, they are less costly than many of the detergents that have been used for such purposes. LPS removal efficiency increased with increasing alkane chain length. 1,2-alkanediols were more effective than terminal alkanediols in the separation of LPS from protein LPS complexes.Type: GrantFiled: May 19, 2010Date of Patent: March 19, 2013Assignee: Fujifilm Diosynth Biotechnologies U.S.A., Inc.Inventors: Philip Alfred Ropp, Michael Van Alen Murray
-
Patent number: 8334146Abstract: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.Type: GrantFiled: April 23, 2008Date of Patent: December 18, 2012Assignee: Redox-Reactive Reagents LLCInventor: John A. McIntyre
-
Patent number: 8133693Abstract: A method of measuring the rate of binding of a binding substance and an analyte, for example in an assay such as an immunoassay, uses an initial step of performing ultrasonication sufficient to disrupt binding between the binding substance and the analyte. After cessation of the ultrasonication, measurements are taken to determine the rate of binding at cessation of said ultrasonication or at a predetermined time thereafter. The ultrasonication results in knowledge of the precise time of the start of the binding reaction which provides a better rate measurement.Type: GrantFiled: May 5, 2006Date of Patent: March 13, 2012Assignee: Orion Diagnostica OyInventor: Kauko Kahma
-
Patent number: 8114612Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction are disclosed. Troponin I and T exist in various conformations and the ratios of monomeric troponin I and T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed are systems to determine the presence of a troponin form or a group of troponin forms in whole blood, serum or plasma samples. Disclosed is a method for improving the recovery of troponin I or T from a surface used in immunoassays. Also disclosed are antibodies which recognize unbound troponin forms, the forms of troponin in binary complexes, the ternary complex of troponin I, T and C, and the conformations of troponin I having intramolecularly oxidized and reduced cysteines.Type: GrantFiled: January 7, 2011Date of Patent: February 14, 2012Assignee: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 8058011Abstract: Methods for measuring an endocrine substance, such as feline insulin, in a biological sample taken from an animal with high accuracy, rapidity and brevity. The methods involve pre-treating a biological sample by removing an autoantibody bound to an endocrine substance present in a sample and measuring the endocrine substance after the pre-treatment. The methods can be used to measure autoantibody bound to an endocrine substance in the sample. Methods for diagnosis and treatment of diseases associated with endocrine substances are disclosed involving measuring an autoantibody value for an endocrine substance in a biological sample.Type: GrantFiled: November 22, 2005Date of Patent: November 15, 2011Assignee: Shibayagi Co., Ltd.Inventors: Masaaki Kojima, Tatsuyuki Hachisu
-
Patent number: 7897404Abstract: The invention relates to a process for the production of a biomolecule-linker conjugate of uniform stochiometry. It especially relates to a conjugate consisting of a biomolecule of a molecular weight between 5 kD and 500 kD and a hydrophilic linker molecule said linker having a molecular weight between 1 and 15 kD and between 4 and 60 charged residues, characterized in that said conjugate comprises at least one biomolecule-linker product of uniform stoichiometry in a pre-selected amount.Type: GrantFiled: August 26, 2001Date of Patent: March 1, 2011Assignee: Roche Diagnostics Operations, Inc.Inventors: Eva Hoess, Herbert Andres, Frederic Donie, Rudolf Vogel, Hans-Peter Josel, Rupert Hermann, Herbert Von Der Eltz
-
Patent number: 7893220Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: July 9, 2008Date of Patent: February 22, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 7709210Abstract: The present invention relates to a method for assessing the likelihood of the presence or formation of fetal heart disease (such as HLHS) in a fetus. In this methodology, the mother, either before or during pregnancy, is tested for the presence of anti-strep antibodies. If positive, the fetus is evaluated and monitored for the presence of fetal heart disease; the fetus can be treated, if appropriate. In addition, either prior to pregnancy or during the first trimester, the mother can be treated to prevent the formation of such antibodies or to neutralize their presence or effect fetal heart tissue.Type: GrantFiled: October 4, 2006Date of Patent: May 4, 2010Assignee: Children's Hospital Medical CenterInventor: Pirooz Eghtesady
-
Patent number: 7695929Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.Type: GrantFiled: November 1, 2007Date of Patent: April 13, 2010Assignee: Ventana Medical Systems, Inc.Inventors: Jerome W. Kosmeder, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz
-
Patent number: 7604946Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. Disclosed is a stabilized composition of troponin; the stabilized composition can comprise a stabilized composition of troponin I, wherein the troponin I is oxidized, the troponin I can be unbound or the troponin I can be in a complex.Type: GrantFiled: May 21, 2004Date of Patent: October 20, 2009Assignee: Biosite IncorporatedInventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 7465587Abstract: This invention relates to assays for an analyte in a liquid sample such as a body fluid. More particularly, the invention relates to a method and apparatus for the detection of a ligand in a body fluid such as urine or blood, which includes an immobilization zone for interfering agents in a sample.Type: GrantFiled: December 3, 2004Date of Patent: December 16, 2008Assignee: Genzyme CorporationInventor: Michael Reece Imrich
-
Patent number: 7361480Abstract: The invention is directed to a method of detecting gluten-induced diseases such as e.g. celiac disease and dermatitis herpetiformis. Said diseases are indicated by the presence of autoantibodies against tissue transglutaminase tTG in the blood The test is carried out on a whole blood sample using tTG liberated from the red blood cells of the blood sample as an autoantigen. The liberated autoantigens react with the autoantibodies in the sample and form antigen-antibody complexes, which are detected. The presence of such complexes indicates the disease. The invention is also directed to the use of the autoantigen in a test and to a test-kit.Type: GrantFiled: April 24, 2002Date of Patent: April 22, 2008Inventors: Markku Mäki, Ilma Korponay-Szabo
-
Patent number: 7320867Abstract: A linker compound has a structure represented by general formula (1) below, where n is an integer of 1 to 6, and X has a structure serving as a multi-branched structure moiety including three or four hydrocarbon derivative chains each having an aromatic amino group at an end and a carbon-nitrogen bond in a backbone.Type: GrantFiled: September 8, 2003Date of Patent: January 22, 2008Assignees: Japan Science and Technology Agency, National University Corporation Kagoshima UniversityInventors: Yasuo Suda, Akio Arano, Shoichi Kusumoto, Michael Sobel
-
Patent number: 7217530Abstract: A process for detecting the forms of the prion pathogens responsible for subacute, transmissible, spongiform encephalopathies, including a macrocyclic adjuvant ligand (AML), free or bound to a support, that is added to a biological sample capable of containing PrPsc, the resulting suspension then being reacted with an anti-PrPsc antibody, and the presence of PrP is then detected.Type: GrantFiled: June 9, 2005Date of Patent: May 15, 2007Assignees: Agence Francaise de Securite Sanitaire des Aliments-AFSSA, Centre National de la Recherche Scientifique-CNRS, Universite Claude Bernard Lyon and BiomerieuxInventors: Aly Moussa, Anthony William Coleman, Patrick Shahgaldian, Eric Da Silva, Ambroise Martin, Adina Nicoleta Lazar, Edwige Leclere, Marilyne Dupin, Herve Perron
-
Patent number: 7205116Abstract: Novel conjugates of 5-fluoro-uracil and novel 5-fluoro-uracil immunogens and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of 5-fluoro-uracil in biological fluids.Type: GrantFiled: February 2, 2006Date of Patent: April 17, 2007Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Dennis Stocker
-
Patent number: 7202041Abstract: The present invention relates to an immunoreaction measuring method for measuring an antigen or antibody contained as a subject substance in a sample, wherein the sample was mixed with at least one compound selected from the group consisting of dicarboxylic acids having a hydroxyl group, dicarboxylic acids having a double bond, straight-chain dicarboxylic acids expressed by the chemical formula (1): HOOC(CH2)nCOOH (n is an integer), and the salts of these dicarboxylic acids, and an antibody or antigen as a specifically binding substance capable of specifically binding to the subject substance, to obtain an acidic reaction solution, and then an antigen-antibody complex, generated by an antigen-antibody reaction of the subject substance with the specifically binding substance in the reaction solution was detected. This makes it possible to improve a measurement value and to relax a limitation of a measurement range due to a zone phenomenon that occurs in an antigen-excess region.Type: GrantFiled: December 9, 2003Date of Patent: April 10, 2007Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Akihito Kamei, Tatsurou Kawamura, Keiko Yugawa
-
Patent number: 7202093Abstract: Provided are a method for easily detecting phosphorylated peptides, namely, proteins, in samples derived from living organisms or the like, a method for selectively adsorbing the phosphorylated peptides, and compounds that are highly coordinated to the phosphorylated peptides and usable in the methods. The complex compound is represented by the formula: wherein X is a linker moiety, and Y is a labeling group. The compound (I) is highly coordinated to a phosphorylated peptide, and has a labeling group. Accordingly, with use of the compound (I), the phosphorylated peptide can be easily identified.Type: GrantFiled: February 23, 2004Date of Patent: April 10, 2007Assignee: Kabushiki Kaisha Nard KenkyushoInventors: Tohru Koike, Akihiko Kawasaki, Tatsuhiro Kobashi, Makoto Takahagi
-
Patent number: 7183067Abstract: A versatile linker compound has a structure represented by following general formula (1), wherein Y has a structure represented by O or NH, and X has a structure serving as a multi-branched moiety including four hydrocarbon derivative chains each of which has an aromatic amino group at an end thereof, and may or may not have a carbon-nitrogen bond in a backbone thereof. With the versatile linker compound, sugar molecules can be two-dimensionally arranged on a surface of a protein-analyzing supporter with high reproducibility. Also, a ligand includes the versatile linker compound and a sugar molecule introduced thereinto.Type: GrantFiled: August 6, 2003Date of Patent: February 27, 2007Assignees: Japan Science and Technology Agency, National University Corporation Kagoshima UniversityInventors: Yasuo Suda, Akio Arano, Hideki Hayashi, Shoichi Kusumoto, Michael Sobel
-
Patent number: 7166423Abstract: Cells can be labeled with products which they secrete and release in an efficient manner by coupling the cells at their surface to a specific binding partner for the product and allowing the product to be captured by the specific binding partner as it is secreted and released. The product-labeled cells can then be further coupled to suitable labels, if desired, and separated according to the presence, absence, or amount of product.Type: GrantFiled: October 21, 1993Date of Patent: January 23, 2007Assignee: Miltenyi Biotec GmbHInventors: Stefan Miltenyi, Andreas Radbruch, Rudi Manz
-
Patent number: 7166476Abstract: The present invention provides an agglutination immunoassay, wherein the agglutination of insoluble carrier particles such as latex are stabilized and uniformized to give good reproducibility, and a reagent therefor. In the agglutination immunoassay which comprises allowing an antigenic substance in a sample to bind to insoluble carrier particles carrying substantially neither antigens nor antibodies thereon, and allowing an antibody or an antibody complex which reacts specifically to the antigenic substance to bind to the antigenic substance to give a selective agglutination of the insoluble carrier particles, a homopolymer prepared by polymerization of a monomer such as 2-methacryloyloxyethyl phosphorylcholine having a phosphorylcholine group and a vinyl group, or a copolymer prepared by polymerization of a monomer having a phosphorylcholine group and a vinyl group, with a monomer having a vinyl group such as n-butyl methacrylate is used.Type: GrantFiled: August 28, 2001Date of Patent: January 23, 2007Assignees: Kyowa Medex Co., Ltd., NOF CorporationInventors: Kayoko Shigenobu, Kenshiro Shuto, Shujiro Sakaki
-
Patent number: 7148024Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: September 13, 2005Date of Patent: December 12, 2006Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 7115383Abstract: Methods, compositions and kits are disclosed. The compounds disclosed comprise an amphetamine moiety and a methamphetamine moiety linked together by a first linking group. A second linking group depends from the first linking group and comprises a functional group. The distance of the amphetamine moiety and the methamphetamine moiety from the point of linkage of the second linking group to the first linking group is approximately the same. The compounds may be linked to labels and used in assays for the detection of amphetamine and/or methamphetamine in samples suspected of containing these drugs.Type: GrantFiled: March 22, 2004Date of Patent: October 3, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Richard F. Parrish, Johnny Valdez, Hshiou-ting Liu
-
Patent number: 7105643Abstract: A monoclonal antibody, and a cell line capable of producing the same, has been produced with the ability to detect the primary metabolites generated from the pyrolysis of smokeable, or “crack”, cocaine. This monoclonal antibody, while being highly specific for anhydroecgonine methyl ester (AEME) and ecgonidine (ECD), does not cross-react at a significant level with the primary cocaine metabolites of powdered or injected cocaine. Also, crack cocaine conjugates capable of evoking an immune response in animals have been produced.Type: GrantFiled: July 30, 2003Date of Patent: September 12, 2006Assignee: The United States of America as represented by the Attorney General of the Dept. of JusticeInventor: Natalie T. Lu
-
Patent number: 7070941Abstract: The invention provides methods and compositions for azide tagging of biomolecules. In one embodiment of the invention, proteins are tagged by metabolic incorporation of prenylated azido-analog substrates. Examples of such analogs are azido farnesyl diphosphate and azido farnesyl alcohol. The azido moiety in the resulting modified proteins provides an affinity tag, which can be chemoselectively captured by an azide-specific conjugation reaction, such as the Staudinger reaction, using a phosphine capture reagent. When the capture agent is biotinylated, the resulting conjugates can be detected and affinity-purified by streptavidin-linked- HRP and streptavidin-conjugated agarose beads, respectively. The invention allows detection and isolation of proteins with high yield, high specificity, and low contamination without harsh treatment of proteins.Type: GrantFiled: November 17, 2003Date of Patent: July 4, 2006Assignee: Board of Regents, The University of Texas SystemInventors: Yingming Zhao, John R. Falck
-
Patent number: 7052855Abstract: A novel monoclonal antibody which specifically binds to apo-B-48 is disclosed. The monoclonal antibody specifically binds to apo-B-48 but does not bind to apo-B-100.Type: GrantFiled: October 14, 2003Date of Patent: May 30, 2006Assignee: Fujirebio, Inc.Inventors: Yoshiaki Uchida, Yoshihiro Kurano
-
Patent number: 7038021Abstract: The object of present invention is to provide an immunoassay for dioxins which can rapidly and simply afford measured values having a good correlation with analytical values of dioxins by the official method (GC/MS method). The above object is achieved by using the monoclonal antibody of the present invention having not only a reactivity with the indicator isomer among 17 kinds of PCDDs and PCDFs each having a predetermined WHO-TEF value, but also a high cross-reactivity with several kinds of dioxin isomers having five or six chlorine atoms which contribute largely to a TEQ value, and also having a stable reactivity with the antigens in a measuring solvent.Type: GrantFiled: July 7, 2004Date of Patent: May 2, 2006Assignee: Kyoto Electronics Manufacturing Co., Ltd.Inventors: Yoko Takagi, Kazuyuki Sawadaishi, Chiwa Kataoka
-
Patent number: 7037669Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I may be employed in assays for the determination of an amphetamine and/or a methamphetamine. Immunogenic conjugates of Formula I may be employed to prepare antibodies for an amphetamine and/or for a methamphetamine for use in assays for the determination of an amphetamine and/or a methamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.Type: GrantFiled: March 22, 2004Date of Patent: May 2, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Khaled A. Yamout, Donald E. Berger, Jr., Mae W. Hu, Hshiou-ting Liu
-
Patent number: 7026166Abstract: The present invention relates to the use of fluorogenic or chromogenic dyes as reporter molecules for detecting cell entry by a specific molecule.Type: GrantFiled: January 21, 2003Date of Patent: April 11, 2006Assignee: Chiron CorporationInventors: Daniel J. Suich, Ronald N. Zuckermann
-
Patent number: 7022492Abstract: Methods, compositions and kits are disclosed. Enzyme conjugates of Formula I are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunogenic conjugates of Formula I are employed to prepare antibodies for an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or for a methylene-dioxymethamphetamine for use in assays for the determination of an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or a methylene-dioxymethamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.Type: GrantFiled: December 15, 2003Date of Patent: April 4, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Yali Yang
-
Patent number: 6995018Abstract: The invention provides methods and compositions for exploiting the discovery that members of the small integrin-binding ligand, n-linked glycoproteins family termed SIBLINGS bind to complement Factor H, and moreover that SIBLINGS proteins, such as BSP, exist in relatively acidic forms. The methods provided can be used to detect SIBLINGS proteins in samples from subjects that are suspected of having tumors or abnormal bone turnover. The invention also provides methods of using SIBLINGS proteins to protect cells from complement mediated lysis. Finally, the discovery allows for the creation of specific binding agents that facilitate the detection of SIBLINGS proteins when they are associated with Factor H.Type: GrantFiled: April 7, 2000Date of Patent: February 7, 2006Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Larry W. Fisher, Neal S. Fedarko, Marian F. Young
-
Patent number: 6991911Abstract: Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy-methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.Type: GrantFiled: December 15, 2003Date of Patent: January 31, 2006Assignee: Dade Behring Inc.Inventors: Yi Feng Zheng, Hshiou-ting Liu
-
Patent number: 6991907Abstract: Antibodies and methods are described for the detection and quantitation of cardiac specific troponin I in samples. Cardiac-specific troponin isoforms exist in various forms in the blood, including free and complexed forms. By selecting antibodies that are insensitive and/or sensitive to these various forms, the present invention can provide immunoassays that more accurately reflect the clinical state of an individual. These described antibodies and methods can be used for providing indicators of myocardial infarction and other cardiac pathologies.Type: GrantFiled: October 12, 2000Date of Patent: January 31, 2006Assignee: Biosite, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 6960457Abstract: This invention provides materials and methods for the site specific attachment of virtually any moiety to a layered silicate surface. The methods involve covalently attaching the moiety to an arginine tag; and contacting the arginine tag with the layered silicate (e.g., mica) surface.Type: GrantFiled: September 3, 1998Date of Patent: November 1, 2005Assignee: Stanford UniversityInventors: James A. Spudich, Steffen Nock, Peter Wagner
-
Patent number: 6951727Abstract: Improved methods, reagents, and kits for quantitation of HLA-DR and/or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP/CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits may be used to assess immune competence, and to direct and monitor immunostimulatory therapies in septic patients exhibiting monocyte deactivation.Type: GrantFiled: February 22, 2002Date of Patent: October 4, 2005Assignee: Becton Dickinson and CompanyInventor: Kenneth A. Davis
-
Patent number: 6939678Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. Disclosed is a stabilized composition of troponin; the stabilized composition can comprise a stabilized composition of troponin I, wherein the troponin I is oxidized, the troponin I can be unbound or the troponin I can be in a complex. Disclosed is a method for improving the recovery of troponin I or T from a surface used in immunoassays.Type: GrantFiled: July 7, 1999Date of Patent: September 6, 2005Assignee: Biosite, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 6893881Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: September 10, 1993Date of Patent: May 17, 2005Assignee: Abbott Laboratories, Inc.Inventors: Øystein Fodstad, Gunnar Kvalheim
-
Patent number: 6887669Abstract: The present invention relates to a method for releasing a ligand from a complex of the ligand with an endogenous protein using a releasing agent.Type: GrantFiled: April 4, 2000Date of Patent: May 3, 2005Assignee: Dade Behring Marburg GmbHInventors: Mark A. Staples, Carolyn J. Haley, Richard F. Parrish, Wesley W. Zmolek
-
Patent number: 6884628Abstract: Multifunctional, polyionic copolymers with molecular architectures and properties optimized for specific applications are synthesized on/or applied to substrate surfaces for analytical and sensing purposes. The coatings are particularly useful for suppression of non-specific interaction, adsorption or attachment of molecular or ionic components present in an analyte solution. Chemical, biochemical or biological groups that are able to recognize, interact with and bind specifically to target molecules in the material containing the analyte to be detected can be coupled to, integrated into, or absorbed to the multifunctional copolymers. These multifunctional copolymer coatings are compatible with a variety of different established methods to detect, sense and quantify the target molecule in an analyte.Type: GrantFiled: April 28, 2000Date of Patent: April 26, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Marcus Textor, Donald L. Elbert, Stephanie Finken, Rolf Hofer, Nicholas D. Spencer, Laurence Ruiz-Taylor
-
Patent number: 6828157Abstract: A method of single parameter and multiparameter characterizing of cells, particularly immunophenotyping of cells, is provided. The method preferably uses antibody coated microspheres which are adapted to bind to specific types of cells. One or more sets of coated microspheres are added simultaneously or sequentially to a suspension of cells and bind the cells they are adapted to bind. Cells may bind to one or more microspheres. The suspension is then filtered to trap bead-cell complexes. The complexes are preferably stained and then examined to characterize the cells, preferably the cells bound to the microspheres. A kit and apparatus for performing the method are also provided.Type: GrantFiled: May 3, 2000Date of Patent: December 7, 2004Inventor: Dan A. Pankowsky
-
Patent number: 6740494Abstract: Disclosed is a method for detecting and quantitating soluble nuclear matrix proteins in body fluids and extracellular media. The method is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of nuclear matrix proteins in soluble form from cells.Type: GrantFiled: May 20, 2002Date of Patent: May 25, 2004Assignee: Matritech, Inc.Inventors: Lee Anne Beausang, Graham P. Lidgard, Thomas E. Miller
-
Patent number: 6706486Abstract: The present invention relates to a method for the quantitative release of natural or recombinant proteins, polypeptides (thermostable immunoligands) able to bind to the Fc-part of immunoglobulins (antibodies, in particular of the IgG class and primarily becoming bound outside the paratope) from complexes in various sample matrixes in order to make these released natural or recombinant proteins, polypeptides or peptides quantitatively available in immunochemical assays and to keep them quantitatively available. The method is characterized by mixing the sample with reagent compound that is able to bind non-specifically to immunoglobulins, and thereafter subjecting the sample to a heat treatment step followed by a cooling step.Type: GrantFiled: February 15, 2001Date of Patent: March 16, 2004Assignee: Amersham Biosciences ABInventor: Franz Steindl
-
Patent number: 6682940Abstract: A method of single parameter and multiparameter characterizing of cells, particularly immunophenotyping of cells, is provided. The method preferably uses antibody-coated microspheres which are adapted to bind to specific types of cells. One or more sets of coated microspheres are contacted simultaneously or sequentially with a suspension of cells and bind the cells they are adapted to bind to form bead-cell complexes. Cells may bind to one or more microspheres. The bead-cell complexes are then separated from the suspension The complexes are preferably stained and then examined to characterize the cells, preferably the cells bound to the microspheres. A method of quantitating a specific cell type is provided. A kit and apparatus for performing the method are also provided.Type: GrantFiled: July 20, 2001Date of Patent: January 27, 2004Inventor: Dan A. Pankowsky
-
Patent number: 6613582Abstract: The present application describes novel uses of ruthenium bipyridyls or palladium porphyrins as photo-activatable crosslinking agents. Crosslinking can be between any two molecules including peptides, proteins, or compounds. Crosslinking occurs in the presence of an electron donor such as ammonium persulfate, and requires only moderate intensity visible light. Crosslinking can be between peptides, polypeptides or lead candidate compounds to unknown target molecules. Reagents utilyzing ruthenium bipyridyls and palladium porphyrins crosslinkers for use in diagnostic and detection scenarios are also disclosed.Type: GrantFiled: May 25, 2000Date of Patent: September 2, 2003Assignee: Board of Regents, The University of Texas SystemInventors: Thomas J. Kodadek, David A. Fancy, Stephen A. Johnston
-
Patent number: 6607891Abstract: A pretreatment method for assaying a substance which comprises mixing a biological specimen with at least one pretreating agent selected from among surfactants and alkali agents, thus releasing binding proteins in the biological specimen from the substance to be assayed and, at the same time, inactivating the proteins by irreversible denaturation to thereby eliminate the effects of the binding proteins coexisting in the biological specimen.Type: GrantFiled: January 31, 2001Date of Patent: August 19, 2003Assignee: Mitsubishi Chemical CorporationInventor: Makoto Takada
-
Patent number: 6582924Abstract: A method for the direct analysis of analyte in keratinized structures, e.g., hair, fingernails and toenails, which comprises preparing a mixture containing a low redox potential compound such as dithiothreitol or dithioerythritol, an enzyme suitable for the degradation of the keratin structure and a sample of the keratin structure; permitting the enzyme to at least substantially degrade the sample of keratin structure, filtering the digest solution to remove substances which may interfere with ligand based analytical methods and subjecting the filtered digest solution to analysis to determine the identity and amount of analyte in the keratin substance sample. To accelerate the method, cupric sulfate may be added to the mixture after degradation of the keratin sample. The enzyme may be a peptidase, endopeptidase or proteinase, with papain, chymopapain, and proteinase K being preferred for use in the invention.Type: GrantFiled: February 23, 1995Date of Patent: June 24, 2003Assignee: Psychemedics CorporationInventor: Werner A. Baumgartner
-
Publication number: 20030096304Abstract: Disclosed is a method for detecting and quantitating soluble nuclear matrix proteins in body fluids and extracellular media. The method is useful for monitoring the viability of cells and tissue, for evaluating the progress of a disease or its treatment, and for evaluating the cytotoxicity of unknown compounds. Also disclosed are methods for inducing the release of nuclear matrix proteins in soluble form from cells.Type: ApplicationFiled: May 20, 2002Publication date: May 22, 2003Applicant: Matritech, Inc.Inventors: Lee Anne Beausang, Graham P. Lidgard, Thomas E. Miller
-
Patent number: 6534270Abstract: Disclosed are biochips having a high detecting sensitivity with readiness in fabrication of microarray, and a method for fabricating the same, in which a solid support wound with fibers is immersed in a solution containing biomolecules to immobilize the biomolecules onto the fiber, and the individual fibers with the biomolecules immobilized thereon are straightened and arranged. The arranged fibers are embedded with a defined material and cut in a direction perpendicular to the lengthwise arrangement direction of the fibers to obtain thin chips. The chips are placed on a substrate to remove the material used for embedding and thereby remain fibers with the immobilized biomolecules on the substrate. This biochip fabrication method immobilizes a great number of biomolecules onto the fibers having a large surface area to enhance the detection sensitivity and allows production of a great number of substrates with an array of biomolecules immobilized simultaneously.Type: GrantFiled: April 12, 2001Date of Patent: March 18, 2003Assignee: LG Electronics Inc.Inventors: Su Hyeon Kim, Je Kyun Park, Tae Han Kim
-
Patent number: RE43979Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: February 5, 2003Date of Patent: February 5, 2013Assignee: Abbott LaboratoriesInventors: Oystein Fodstad, Gunnar Kvalheim